The inflammatory hypothesis of Alzheimer's disease, which states that anti-inflammatory drugs could have beneficial effects on the pathophysiology of Alzheimer's disease, has been extensively investigated in clinical, epidemiological and basic research studies over the last 20 years. However, despite much hope, the hypothesis remains unproven. Although the results from the first small clinical trial with an anti-inflammatory agent in Alzheimer's disease appeared promising, subsequent trials with a variety of anti-inflammatory agents have failed to show beneficial effects. There are many potential reasons for this including drug selection, drug dose, timing and duration of treatment. This article reviews evidence in support of the inflammatory hypothesis in Alzheimer's disease, as well as the progress of clinical trials using specific anti-inflammatory treatment regimens. It is concluded that such treatments should not be recommended, although additional investigation is warranted.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1586/14737175.4.5.793 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!